BMS-207147, Sch 56592, and voriconazole are all investigational triazole antifungal agents that are in different stages of in vitro and clinical investigation (2, 3, 7) . Previous in vitro studies of these agents indicate a spectrum of antifungal activity broader than that of fluconazole (1-4, 6, 7, 10, 11) . All three investigational triazoles are lipophilic and exhibit activity similar to that of itraconazole against clinically important yeast isolates (2, 3, 7) . However, earlier investigations have included limited numbers of clinical yeast isolates and have compared each of these new agents individually against fluconazole and itraconazole. None of the previously published reports have compared all three investigational triazoles simultaneously against a large (Ͼ1,000 isolates) collection of recent, clinically important Candida isolates. In this study, we compare the in vitro activities of BMS-207147, Sch 56592, and voriconazole with those of fluconazole and itraconazole against 1,300 clinical isolates of Candida spp. from bloodstream infections. The in vitro antifungal susceptibility test method employed was the broth microdilution adaptation of the macrodilution reference method described in National Committee for Clinical Laboratory Standards (NCCLS) document M27-A (5).
MATERIALS AND METHODS

Organisms.
A total of 1,300 bloodstream isolates of Candida spp. obtained from over 50 U.S. medical centers between 1992 and 1997 were selected for testing. Approximately 550 isolates were obtained as part of a population-based survey of invasive mycoses conducted by the Centers for Disease Control and Prevention (8) , and the remainder were from various medical centers throughout the United States. Included were C. albicans (660 isolates), C. parapsilosis (221 isolates), C. glabrata (217 isolates), C. tropicalis (139 isolates), C. krusei (33 isolates), and other Candida spp. (30 isolates, including 7 of C. lusitaniae, 7 of C. gulliermondii, 3 of C. famata, 2 of C. rugosa, 1 of C. lipolytica, 1 of C. lambica, and 9 of Candida unidentified to species level). All isolates were identified by standard methods (12) and stored as water suspensions at ambient temperature until used in the study. Prior to testing, each isolate was subcultured at least twice on potato dextrose agar plates (Remel, Lenexa, Kans.) to ensure purity and optimal growth.
Antifungal agents. Standard antifungal powders of BMS-207147 (Bristol-Myers Squibb), Sch 56592 (Schering-Plough), voriconazole (Pfizer), fluconazole (Pfizer), and itraconazole (Janssen) were obtained from their respective manufacturers. Stock solutions were prepared in dimethyl sulfoxide (BMS-207147 and voriconazole), polyethylene glycol (Sch 56592 and itraconazole), or water (fluconazole). Serial twofold dilutions of each antifungal agent were prepared exactly as outlined in NCCLS document M27-A (5). Final dilutions were made in RPMI 1640 medium (Sigma Chemical Co., St. Louis, Mo.) buffered to pH 7.0 with 0.165 M morpholinepropanesulfonic acid (MOPS) buffer (Sigma). The final concentration of the solvent did not exceed 1% in any well. Aliquots (0.1 ml) of each antifungal agent at a 2ϫ final concentration were dispensed into the wells of plastic microdilution trays by using a Quick Spense II System (Dynatech Laboratories, Chantilly, Va.). The trays were sealed and frozen at Ϫ70°C until they were used.
Antifungal susceptibilities studies. Broth microdilution testing was performed in accordance with the guidelines in NCCLS document M27-A (5) by using the spectrophotometric method of inoculum preparation, an inoculum concentration of (1.5 Ϯ 1.0) ϫ 10 3 cells/ml, and RPMI 1640 medium buffered to pH 7.0 with MOPS. A 100-l yeast inoculum was added to each well of the microdilution trays. The final concentrations of the antifungal agents were 0.008 to 8.0 g/ml for BMS-207147, Sch 56592, voriconazole, and itraconazole and 0.12 to 128 g/ml for fluconazole. The trays were incubated in air at 35°C, and MIC endpoints were read after 48 h of incubation. Drug-free and yeast-free controls were included.
Following incubation, the broth microdilution wells were examined with the aid of a reading mirror; the growth in each well was compared with that of the growth control (drug-free) well. The MIC of each triazole was defined as the lowest concentration resulting in 80% inhibition of growth compared to that for untreated controls (5) . The data are reported as the concentrations of each antifungal agent necessary to inhibit 50% (MIC 50 ) and 90% (MIC 90 ) of the isolates tested.
Quality control. Quality was controlled by testing the following strains recommended by NCCLS document M27-A (5): C. parapsilosis ATCC 22019 and C. krusei ATCC 6258. s, 0.5, 1.0, and 0.5 g/ml, respectively) against these isolates. C. albicans was the most susceptible species (MIC 90 s, 0.03, 0.06, and 0.06 g/ml, respectively), and C. glabrata was the least susceptible (MIC 90 s, 4.0, 4.0, and 2.0 g/ml, respectively) to the three investigational triazoles. BMS-207147, Sch 56592, and voriconazole were all more active than both itraconazole and fluconazole against C. albicans, C. parapsilosis, C. tropicalis, and C. krusei. Voriconazole was also more active than both itraconazole and fluconazole against C. glabrata (MIC 90 s, 2.0, 4.0, and 64 g/ml, respectively). BMS-207147 and Sch 56592 were comparable to itraconazole (MIC 90 , 4.0 g/ml) but more active than fluconazole against C. glabrata (MIC 90 , 4.0 versus 64 g/ml).
RESULTS AND DISCUSSION
One hundred forty-six strains (121 of C. glabrata, 14 of C. krusei, 6 of C. parapsilosis, and 4 of C. albicans) were inhibited by 16-to 32-g/ml fluconazole (dose-dependently susceptibility) (9) . The MIC 90 s of each of the investigational triazoles ranged from 1.0 to 2.0 g/ml for these isolates and were not significantly different from those observed for the overall isolate collection (data not shown).
Among the 1,300 isolates studied, a total of 53 strains (12 of C. albicans, 13 of C. krusei, 25 of C. glabrata, and 3 of C. tropicalis) were resistant to both fluconazole (MIC, Ն64 g/ml) and itraconazole (MIC, Ն1 g/ml) (9). The MICs of BMS-207147 (0.03 to Ͼ8.0 g/ml; mode, Ն8.0 g/ml), Sch 56592 (0.03 to Ͼ8.0 g/ml; mode, Ն8.0 g/ml), and voriconazole (0.25 to Ͼ16 g/ml; mode, Ն16 g/ml) were also elevated with these isolates (Table 2) . These results support and extend findings reported previously (2, 3, 7) . We found that all three investigational triazoles were more active than fluconazole against all of the Candida spp. tested. In almost every case, the in vitro potencies of BMS-207147, Sch 56592, and voriconazole were comparable to one another and slightly greater than that of itraconazole. In contrast to the study of Fung-Tomc et al. (2) , ours found BMS-207147 to be quite active against C. tropicalis and to have measurable activity against C. glabrata. Similar to the studies of Marco et al. (3) and of Pfaller et al. (7), ours found that those isolates of Candida spp. with decreased susceptibility to fluconazole and itraconazole were also less susceptible to the investigational triazoles, suggesting cross-resistance that is likely to be mediated by one or more efflux mechanisms (13) .
In summary, we found that BMS-207147, Sch 56592, and voriconazole all exhibit excellent in vitro activity against clinically significant isolates of Candida spp. These agents are slightly more active than itraconazole and offer important advantages over fluconazole in terms of spectrum and potency. As always, the translation of this in vitro activity into clinical efficacy must be established. Further investigation of these exciting new agents is encouraged.
